Original articleEfficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis
Section snippets
Methods
Detailed methods for REVEAL have been published.11 Methods relevant to the current subgroup analyses are included herein.
REVEAL period A safety and efficacy
Of 1212 patients entering the study at week 0, 814 were randomized to adalimumab treatment and 398 were randomized to placebo. As previously reported, baseline demographics and disease characteristics were similar between treatment groups, including duration of psoriasis, baseline PASI score, BSA involvement, and baseline PGA.11 The mean (±SD) baseline weight for placebo-treated patients was 94.1 ± 23.0 kg and for adalimumab-treated patients was 92.3 ± 23.0 kg. In all, 31 patients discontinued
Discussion
As previously published, REVEAL was a randomized, double-blind, placebo-controlled clinical trial of subcutaneously administered adalimumab that demonstrated significant efficacy at 16 weeks for the treatment of moderate to severe psoriasis (as measured by PASI 75 score, at least 90% improvement from baseline in the PASI score, 100% improvement from baseline in the PASI score, mean percentage PASI score improvement, and PGA of “clear” or “minimal”).11 REVEAL also demonstrated comparable AE
References (19)
- et al.
Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris
J Am Acad Dermatol
(1985) - et al.
The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004
J Am Acad Dermatol
(2009) - et al.
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction
J Investig Dermatol Symp Proc
(2004) - et al.
Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene
Am J Hum Genet
(2006) - et al.
Prevalence of cardiovascular risk factors in patients with psoriasis
J Am Acad Dermatol
(2006) - et al.
Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial
J Am Acad Dermatol
(2008) - et al.
Efficacy of etanercept in an integrated multistudy database of patients with psoriasis
J Am Acad Dermatol
(2006) - et al.
The effect of weight on the efficacy of biologic therapy in patients with psoriasis
J Am Acad Dermatol
(2008) Environment and genetics in psoriasis
Ann Clin Res
(1976)
Cited by (137)
Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2 — Management of Special Populations, Patients With Comorbid Conditions, and Risk
2022, Actas Dermo-SifiliograficasEvaluating the Efficacy and Safety of Bimekizumab for Plaque Psoriasis and Psoriatic Arthritis: An Expert Consensus Panel Report
2024, SKIN: Journal of Cutaneous MedicineSystemic treatment of psoriasis in special population
2024, Indian Journal of Dermatology, Venereology and LeprologyClinical features, therapeutic choice and response by phototype in psoriasis: analysis of the French PsoBioTeq cohort
2023, Clinical and Experimental Dermatology
Funding for manuscript development was provided by Abbott Laboratories, with editorial support provided by Michael A. Nissen, ELS, of Abbott Laboratories, and Arbor Communications Inc.
Disclosure: Dr Menter is a consultant and member of the advisory boards and speakers bureaus of Abbott Laboratories, Amgen, Astellas, Centocor, Genentech, and Wyeth; he is a consultant and investigator for Eli Lilly; and he has received investigator funding from Abbott Laboratories, Amgen, Astellas, Centocor, Genentech, and Novo Nordisk. Dr Gordon has received investigator funding and consulting fees from and serves as a member of the advisory boards of Abbott Laboratories, Amgen, Centocor, Galderma, and Novo Nordisk. Dr Leonardi is a consultant for Abbott Laboratories, Amgen, Centocor, and Genentech and is an investigator for Abbott Laboratories, Allergan, Altana, Amgen, Astellas, Biogen, Bristol-Myers Squibb, Centocor, CombinatoRx, Fujisawa, Galderma, Genentech, RTL, Schering-Plough, Serono, Vitae, and 3M Pharmaceuticals; he also received an educational grant from Amgen and Genentech, and is part of the speakers bureaus for Abbott Laboratories, Amgen, Centocor, Genentech, and Warner Chilcott. Ms Gu and Dr Goldblum are employees of Abbott Laboratories.
Reprints not available from the authors.